Grifois, S.A. (GRFS)

Price$8.60

Favorite Metrics

Price vs S&P 500 (26W)-23.88%

Price vs S&P 500 (4W)-2.44%

Market Capitalization$6.88B

P/E Ratio (Annual)14.53x

Indicated Dividend Yield (Annual)0.00%

All Metrics

P/CF (Annual)5.58x

Book Value / Share (Quarterly)$9.12

P/TBV (Annual)2.58x

Indicated Dividend (Annual)$0.18

Revenue Growth (3Y)7.46%

Cash Flow / Share (Quarterly)$1.08

Payout Ratio (TTM)56.83%

Price vs S&P 500 (YTD)-13.31%

Gross Margin (TTM)38.00%

Net Profit Margin (TTM)5.34%

EPS (TTM)$0.69

10-Day Avg Trading Volume3.13M

EPS Excl Extra (TTM)$0.69

Revenue Growth (5Y)7.10%

EPS (Annual)$0.70

Dividend / Share (Annual)$0.22

ROI (Annual)2.70%

Gross Margin (Annual)38.00%

Net Profit Margin (5Y Avg)3.14%

Cash / Share (Quarterly)$1.49

P/E Basic Excl Extra (TTM)14.53x

Revenue Growth QoQ (YoY)0.30%

EPS Growth (5Y)-8.12%

P/E Normalized (Annual)14.53x

ROA (Last FY)2.04%

Revenue Growth TTM (YoY)4.32%

EBITD / Share (TTM)$2.36

ROE (5Y Avg)3.64%

Operating Margin (TTM)16.52%

Cash Flow / Share (Annual)$1.08

P/B Ratio1.11x

P/B Ratio (Quarterly)1.25x

Net Income / Employee (Annual)$0

EV / Revenue (TTM)1.85x

Net Interest Coverage (TTM)2.22x

ROA (TTM)2.00%

EPS Growth QoQ (YoY)41.77%

EV / EBITDA (TTM)10.16x

EPS Incl Extra (Annual)$0.70

Current Ratio (Annual)2.51x

Quick Ratio (Quarterly)0.88x

3-Month Avg Trading Volume1.95M

52-Week Price Return17.30%

EV / Free Cash Flow (Annual)22.25x

P/E Incl Extra (TTM)14.53x

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.40

P/S Ratio (Annual)0.78x

Asset Turnover (Annual)0.38x

52-Week High$13.70

Operating Margin (5Y Avg)14.07%

EPS Excl Extra (Annual)$0.70

CapEx CAGR (5Y)7.44%

Tangible BV CAGR (5Y)-6.46%

26-Week Price Return-19.90%

Quick Ratio (Annual)0.88x

13-Week Price Return-18.94%

Total Debt / Equity (Annual)1.83x

Current Ratio (Quarterly)2.51x

Enterprise Value$16,353.84

Revenue / Share Growth (5Y)7.25%

Asset Turnover (TTM)0.37x

Book Value / Share Growth (5Y)0.75%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)1.36x

Pretax Margin (Annual)8.17%

Cash / Share (Annual)$1.45

3-Month Return Std Dev36.59%

Gross Margin (5Y Avg)38.23%

Net Income / Employee (TTM)$0

EBITDA CAGR (5Y)3.84%

EBITDA Interim CAGR (5Y)-14.15%

ROE (Last FY)7.63%

Net Interest Coverage (Annual)2.40x

EPS Basic Excl Extra (Annual)$0.70

P/FCF (TTM)9.36x

Receivables Turnover (TTM)10.20x

EV / Free Cash Flow (TTM)22.25x

Total Debt / Equity (Quarterly)1.68x

EPS Incl Extra (TTM)$0.69

Receivables Turnover (Annual)10.20x

ROI (TTM)2.73%

Dividend Growth Rate (5Y)2.54%

P/S Ratio (TTM)0.78x

Pretax Margin (5Y Avg)6.16%

Revenue / Share (Annual)$13.02

Tangible BV / Share (Annual)$4.40

Forward P/E10.85x

Price vs S&P 500 (52W)-12.53%

P/E Ratio (TTM)14.53x

EPS Growth TTM (YoY)156.87%

Year-to-Date Return-11.55%

5-Day Price Return5.93%

EPS Normalized (Annual)$0.70

ROA (5Y Avg)1.00%

Net Profit Margin (Annual)5.34%

Month-to-Date Return5.67%

EBITD / Share (Annual)$2.24

EPS Growth (3Y)24.46%

Operating Margin (Annual)16.48%

LT Debt / Equity (Annual)1.55x

P/CF (TTM)5.58x

ROI (5Y Avg)1.31%

P/E Excl Extra (TTM)14.53x

LT Debt / Equity (Quarterly)1.42x

EPS Basic Excl Extra (TTM)$0.69

P/TBV (Quarterly)2.58x

Payout Ratio (Annual)31.84%

P/B Ratio (Annual)1.25x

Dividend / Share (TTM)$0.22

Inventory Turnover (TTM)1.36x

Pretax Margin (TTM)8.17%

Book Value / Share (Annual)$9.12

Price vs S&P 500 (13W)-19.63%

Net Margin Growth (5Y)-14.34%

Dividend Yield (TTM)2.19%

Beta0.78x

P/FCF (Annual)9.36x

Revenue / Share (TTM)$12.98

ROE (TTM)7.56%

52-Week Low$8.01

About

Grifols is a global specialty plasma therapeutics company that develops, manufactures, and distributes protein-based medicines for immunological deficiencies, hemophilia, and other chronic and life-threatening conditions. The company's portfolio serves both diagnostic and therapeutic applications across rare and inherited diseases with significant unmet medical needs. Grifols generates the majority of its revenue from the United States market.